We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

54 hedge funds and large institutions have $132M invested in Kiniksa Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

5.84% less ownership

Funds ownership: 86.89% → 81.05% (-5.8%)

11% less funds holding

Funds holding: 61 → 54 (-7)

41% less capital invested

Capital invested by funds: $224M → $132M (-$91.4M)

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
54
Holders Change
-7
Holders Change %
-11.48%
% of All Funds
1.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
25
Reduced
15
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
ACH
ArrowMark Colorado Holdings
Colorado
+$2.89M
2
Victory Capital Management
Victory Capital Management
Texas
+$1.75M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.66M
4
Bank of America
Bank of America
North Carolina
+$1.4M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.16M

Top Sellers

1
VC
Vivo Capital
California
-$11.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.59M
3
First Manhattan
First Manhattan
New York
-$866K
4
FCMI
Foresite Capital Management IV
California
-$866K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$849K
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$325K -$17.7K -1,600 -4%
Charles Schwab
27
Charles Schwab
California
$310K +$4.32K +391 +1%
Squarepoint
28
Squarepoint
New York
$246K -$105K -9,504 -25%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$183K – – –
Swiss National Bank
30
Swiss National Bank
Switzerland
$166K – – –
AllianceBernstein
31
AllianceBernstein
Tennessee
$163K +$58.6K +5,300 +38%
CS
32
Credit Suisse
Switzerland
$153K +$199K +18,011 New
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$141K -$420 -38 -0.2%
HSBC Holdings
34
HSBC Holdings
United Kingdom
$125K +$163K +14,730 New
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$116K – – –
M&T Bank
36
M&T Bank
New York
$115K +$34.2K +3,092 +30%
SO
37
STRS Ohio
Ohio
$114K – – –
Barclays
38
Barclays
United Kingdom
$98K +$2.92K +264 +2%
Manulife (Manufacturers Life Insurance)
39
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$92K +$1.47K +133 +1%
UBS Group
40
UBS Group
Switzerland
$80K +$84.3K +7,629 +440%
AIG
41
American International Group
New York
$75K -$674 -61 -0.7%
Wells Fargo
42
Wells Fargo
California
$66K +$5.67K +513 +7%
JP Morgan Chase
43
JP Morgan Chase
New York
$39K +$8.2K +742 +19%
Deutsche Bank
44
Deutsche Bank
Germany
$31K -$63.1K -5,707 -60%
Legal & General Group
45
Legal & General Group
United Kingdom
$22K – – –
BNP Paribas Financial Markets
46
BNP Paribas Financial Markets
France
$18.9K +$7.5K +679 +44%
Citigroup
47
Citigroup
New York
$10K -$34.8K -3,152 -73%
Bank of Montreal
48
Bank of Montreal
Ontario, Canada
$10K +$541 +49 +4%
AIP
49
Ameritas Investment Partners
Nebraska
$8K – – –
PHK
50
Point72 Hong Kong
Hong Kong
$3K -$6.97K -631 -64%
1
2
3

KNSA Hedge Fund Activity: Q3 2019 in Review

54 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q3 2019, worth a combined $132M — down 41% from $224M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of KNSA and 3 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 25 added.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $2.89M. The largest seller was Vivo Capital, exiting entirely with an estimated $11.4M sold.

  • 54 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q3 2019, down from 61 in Q2 2019.
  • Funds reported $132M of Kiniksa Pharmaceuticals stock for Q3 2019, down 41% quarter-over-quarter.
  • 3 funds opened new Kiniksa Pharmaceuticals positions in Q3 2019 and 10 closed out, a net change of -7 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $2.89M added.
  • The largest Kiniksa Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $11.4M sold.

Based on aggregated 13F filings for Q3 2019.